Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remodulin Open-Label Extension in PAH
NCT02882126Phase 4Withdrawn
- Sponsor
- United Therapeutics Corporation
- Start
- Jun 2017
- Primary completion
- Jun 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Planned start Jun 2017; status: withdrawn.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02882126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882126.